Since their first Food and Drug Administration approval in 2010, direct oral anticoagulants (DOACs) have grown in use worldwide and have become the most common initially prescribed oral anticoagulation drug for patients with newly diagnosed atrial fibrillation. However, the high costs still hinder their utilization, especially in low and middle-income countries. Furthermore, in certain conditions, especially mechanical heart valves and rheumatic mitral stenosis, vitamin K antagonists (VKAs) remain the only drugs with established safety and efficacy., Data from more than […]